Skip to main content
logo
Soleno Therapeutics, Inc. (SLNO)
May 18, 2026 - SLNO was delisted (reason: acquired by NBIX)
53.01
0.00 (0.00%)
Inactive · Last trade price on May 15, 2026

Soleno Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
285.01190.41----
Revenue Growth
------
Gross Profit
281.11187.71----
Operating Income
89.4914.95-184.43-38.67-25.11-32.26
Net Income
95.6320.48-175.85-38.99-24.07-30.91
Earnings Per Share
1.770.39-4.38-2.36-2.87-5.81
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
528.98506.09318.65169.6814.621.3
Total Debt
54.2852.5552.830.40.160.46
Net Cash (Debt)
474.7453.54265.82169.2814.4520.85
Net Cash Growth
100.16%70.62%57.03%1071.72%-30.70%-57.52%
Net Cash Per Share
8.778.666.6210.261.723.92

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
105.5346.8-69.1-24.94-20.78-27.77
Capital Expenditures
-0.11-0.07-0.22--0.01-0.02
Free Cash Flow
105.4246.73-69.31-24.94-20.79-27.79
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
98.63%98.58%----
Operating Margin
31.40%7.85%----
Pretax Margin
34.94%10.97%----
Profit Margin
33.55%10.75%----
FCF Margin
36.99%24.54%----

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
30.00121.45----
Forward PE
11.1613.68----
P/FCF Ratio
26.2153.22----
PS Ratio
9.6913.06----